Early Oral Immunotherapy With Pasteurized Egg White in Egg-Allergic Children Under 2 Years of Age

IF 4 2区 医学 Q2 ALLERGY
Silvia Karina Carrión Sari, Luis Martínez-Lostao, Carlos Colás Sanz, María Teresa Sobrevía Elfau
{"title":"Early Oral Immunotherapy With Pasteurized Egg White in Egg-Allergic Children Under 2 Years of Age","authors":"Silvia Karina Carrión Sari,&nbsp;Luis Martínez-Lostao,&nbsp;Carlos Colás Sanz,&nbsp;María Teresa Sobrevía Elfau","doi":"10.1002/clt2.70155","DOIUrl":null,"url":null,"abstract":"<p>To the Editor:</p><p>In Europe, the overall raw incidence of egg allergy in the first 2 years of life is 0.84% (0.78% in Spain) [<span>1</span>]. Few publications are available on the safety of oral immunotherapy (OIT) in young children [<span>2-4</span>].</p><p>Our objective was to assess the possibility of desensitization after OIT with pasteurized egg white in patients under 2 years of age with egg allergy. This was a prospective observational analytical study in which children under 2 years of age with IgE-mediated egg allergy were recruited and received OIT with pasteurized liquid egg white (Huevos Guillén S.L.).</p><p>Children attending the Allergology Department of the Hospital Clínico Lozano Blesa in Zaragoza, Spain, were recruited. All patients who met the inclusion criteria were included consecutively. The study was approved by the Research Ethics Committee of Autonomous Community of Aragón and informed consent was obtained from both parents.</p><p>Inclusion criteria were history of immediate reaction (&lt; 1h) after ingestion of egg; IgE &gt; 0.35 kU/L and/or skin prick test (SPT) wheal ≥ 3 mm to at least 1 egg fraction (egg white, yolk, ovalbumin or ovomucoid); and a positive oral food challenge (OFC) with boiled egg. OFC was performed on all patients except those with a history of anaphylactic reaction (diagnosed according to Sampson's criteria [<span>5</span>]) or ≥ 2 immediate reactions in the last 3 months. SPT and determinations of specific IgE (sIgE), specific IgG4 (sIgG4), and sIgE/total IgE ratio were performed at T1 (baseline), at T2 (end of dose escalation phase), and at T3 (6 months after T2).</p><p>During the induction phase, increasing doses of pasteurized egg white were administered weekly in the hospital (Supporting Information S1: Table S1). The final dose was 30 mL of egg white (3300 mg of protein, the amount of egg white in a medium-sized egg). Between the increments, the dose tolerated in the clinic was repeated daily at home until the next visit. An OFC with natural raw egg was performed during the T2 visit to verify total desensitization. The maintenance phase, lasting 6 months, consisted of administration of the total dose (30 mL) on alternate days for a period of 15 days, followed by ingestion of 1 egg prepared in different ways (boiled, scrambled, baked, etc.), including undercooked preparations (mayonnaise, mousse, etc.) at least 3 times a week, until the T3 follow-up visit. Adherence was monitored by parental reporting.</p><p>A total of 31 patients were recruited, 17 (54.8%) females and 14 (45.2%) males. Mean age at presentation of the first symptom was 9.6 months (SD 2.48). Median age at the start of OIT was 14 months (range 9–26). Median age at diagnosis was 11 months (IQR: 3.71). Fifteen (48.39%) patients had a history of atopic dermatitis; 11 (35.48%) patients had previously presented wheezing. Eleven (35.48%) patients had a history of other food allergies, and 15 (53.57%) had a family history of allergic diseases.</p><p>Statistically significant decreases (<i>p</i> ≤ 0.001) in SPT wheal diameter, sIgE levels, and sIgE/total IgE ratio were observed (Table 1). Higher sIgG4 was seen at T2, followed by a slight decline at T3 (Figure 1), although no significant differences were observed.</p><p>During the induction phase, 24 patients (77.42%) had adverse reactions: 71 (65.14%) mild skin reactions; 31 (28.44%) gastrointestinal effects; and 7 (6.42%) rhinoconjunctivitis. Most events resolved spontaneously or with oral antihistamines. None required adrenaline. OFC was negative in 30 patients at T2. One patient, who reached an OIT dose of 22 mL, discontinued the study for family reasons, and at 6 months could tolerate only food containing baked egg and small amounts of boiled egg. Another patient with a negative OFC subsequently refused the maintenance ingestions and accepted only baked egg and egg traces. Six patients (19.35%) developed reactions in the maintenance phase: 4 cutaneous and 2 gastrointestinal. All these reactions were mild and did not prevent the patients from subsequently continuing to consume eggs.</p><p>Giavi [<span>2</span>] reported a 36% rate of negative OFCs at 6 months. In our study, during follow-up, 93.54% (29/31) of the parents reported that their children remained in a state of desensitization, so OFC was not performed. The proportion achieving complete desensitization (absence of reaction to a medium-sized egg, ranging from raw to thoroughly cooked) was higher than in previous studies (64%–84%) [<span>4, 6</span>]. OIT is not risk-free, but our rate of adverse reactions is in line with published systematic reviews [<span>7</span>]. None of our patients needed adrenaline, whereas in a study in older children conducted by Vazquez-Ortiz et al. [<span>8</span>], it was required in 26% of 50 children aged 5–18 years. Immunological changes after OIT similar to our series have been previously described in several studies [<span>2-4</span>]. One strength of our study is the young age of our patients: recent trials with peanuts and milk show that early intervention improves the outcomes of OIT [<span>9</span>]. Another is the use of pasteurized egg white, selected for this study for its stability, reproducibility, allergenicity, ease of dosing, low cost, and microbiological safety.</p><p>Our study is limited by the relatively short follow-up period without assessment of long-term tolerance, the lack of randomization, and the potential compromise of statistical inference due to the absence of a control group. There is also a potential for selection bias (e.g., families were highly motivated to pursue OIT in a tertiary center).</p><p>Although the results of our series seem to indicate that early oral immunotherapy is effective for the development of egg desensitization, we believe that further controlled and randomized studies are required to confirm this statement.</p><p><b>Silvia Karina Carrión Sari:</b> funding acquisition, investigation, formal analysis, writing – original draft, visualization, software, data curation. <b>Luis Martínez-Lostao:</b> writing – review and editing, supervision, investigation, project administration. <b>Carlos Colás Sanz:</b> supervision, methodology, writing – review and editing, conceptualization, investigation. <b>María Teresa Sobrevía Elfau:</b> conceptualization, methodology, investigation, writing – review and editing, supervision, validation.</p><p>This study has been funded by the SEAIC (Spanish Society of Allergology and Clinical Immunology) Foundation Ref: 22A12.</p><p>The authors declare no conflicts of interest.</p><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 3","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12945664/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.70155","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

To the Editor:

In Europe, the overall raw incidence of egg allergy in the first 2 years of life is 0.84% (0.78% in Spain) [1]. Few publications are available on the safety of oral immunotherapy (OIT) in young children [2-4].

Our objective was to assess the possibility of desensitization after OIT with pasteurized egg white in patients under 2 years of age with egg allergy. This was a prospective observational analytical study in which children under 2 years of age with IgE-mediated egg allergy were recruited and received OIT with pasteurized liquid egg white (Huevos Guillén S.L.).

Children attending the Allergology Department of the Hospital Clínico Lozano Blesa in Zaragoza, Spain, were recruited. All patients who met the inclusion criteria were included consecutively. The study was approved by the Research Ethics Committee of Autonomous Community of Aragón and informed consent was obtained from both parents.

Inclusion criteria were history of immediate reaction (< 1h) after ingestion of egg; IgE > 0.35 kU/L and/or skin prick test (SPT) wheal ≥ 3 mm to at least 1 egg fraction (egg white, yolk, ovalbumin or ovomucoid); and a positive oral food challenge (OFC) with boiled egg. OFC was performed on all patients except those with a history of anaphylactic reaction (diagnosed according to Sampson's criteria [5]) or ≥ 2 immediate reactions in the last 3 months. SPT and determinations of specific IgE (sIgE), specific IgG4 (sIgG4), and sIgE/total IgE ratio were performed at T1 (baseline), at T2 (end of dose escalation phase), and at T3 (6 months after T2).

During the induction phase, increasing doses of pasteurized egg white were administered weekly in the hospital (Supporting Information S1: Table S1). The final dose was 30 mL of egg white (3300 mg of protein, the amount of egg white in a medium-sized egg). Between the increments, the dose tolerated in the clinic was repeated daily at home until the next visit. An OFC with natural raw egg was performed during the T2 visit to verify total desensitization. The maintenance phase, lasting 6 months, consisted of administration of the total dose (30 mL) on alternate days for a period of 15 days, followed by ingestion of 1 egg prepared in different ways (boiled, scrambled, baked, etc.), including undercooked preparations (mayonnaise, mousse, etc.) at least 3 times a week, until the T3 follow-up visit. Adherence was monitored by parental reporting.

A total of 31 patients were recruited, 17 (54.8%) females and 14 (45.2%) males. Mean age at presentation of the first symptom was 9.6 months (SD 2.48). Median age at the start of OIT was 14 months (range 9–26). Median age at diagnosis was 11 months (IQR: 3.71). Fifteen (48.39%) patients had a history of atopic dermatitis; 11 (35.48%) patients had previously presented wheezing. Eleven (35.48%) patients had a history of other food allergies, and 15 (53.57%) had a family history of allergic diseases.

Statistically significant decreases (p ≤ 0.001) in SPT wheal diameter, sIgE levels, and sIgE/total IgE ratio were observed (Table 1). Higher sIgG4 was seen at T2, followed by a slight decline at T3 (Figure 1), although no significant differences were observed.

During the induction phase, 24 patients (77.42%) had adverse reactions: 71 (65.14%) mild skin reactions; 31 (28.44%) gastrointestinal effects; and 7 (6.42%) rhinoconjunctivitis. Most events resolved spontaneously or with oral antihistamines. None required adrenaline. OFC was negative in 30 patients at T2. One patient, who reached an OIT dose of 22 mL, discontinued the study for family reasons, and at 6 months could tolerate only food containing baked egg and small amounts of boiled egg. Another patient with a negative OFC subsequently refused the maintenance ingestions and accepted only baked egg and egg traces. Six patients (19.35%) developed reactions in the maintenance phase: 4 cutaneous and 2 gastrointestinal. All these reactions were mild and did not prevent the patients from subsequently continuing to consume eggs.

Giavi [2] reported a 36% rate of negative OFCs at 6 months. In our study, during follow-up, 93.54% (29/31) of the parents reported that their children remained in a state of desensitization, so OFC was not performed. The proportion achieving complete desensitization (absence of reaction to a medium-sized egg, ranging from raw to thoroughly cooked) was higher than in previous studies (64%–84%) [4, 6]. OIT is not risk-free, but our rate of adverse reactions is in line with published systematic reviews [7]. None of our patients needed adrenaline, whereas in a study in older children conducted by Vazquez-Ortiz et al. [8], it was required in 26% of 50 children aged 5–18 years. Immunological changes after OIT similar to our series have been previously described in several studies [2-4]. One strength of our study is the young age of our patients: recent trials with peanuts and milk show that early intervention improves the outcomes of OIT [9]. Another is the use of pasteurized egg white, selected for this study for its stability, reproducibility, allergenicity, ease of dosing, low cost, and microbiological safety.

Our study is limited by the relatively short follow-up period without assessment of long-term tolerance, the lack of randomization, and the potential compromise of statistical inference due to the absence of a control group. There is also a potential for selection bias (e.g., families were highly motivated to pursue OIT in a tertiary center).

Although the results of our series seem to indicate that early oral immunotherapy is effective for the development of egg desensitization, we believe that further controlled and randomized studies are required to confirm this statement.

Silvia Karina Carrión Sari: funding acquisition, investigation, formal analysis, writing – original draft, visualization, software, data curation. Luis Martínez-Lostao: writing – review and editing, supervision, investigation, project administration. Carlos Colás Sanz: supervision, methodology, writing – review and editing, conceptualization, investigation. María Teresa Sobrevía Elfau: conceptualization, methodology, investigation, writing – review and editing, supervision, validation.

This study has been funded by the SEAIC (Spanish Society of Allergology and Clinical Immunology) Foundation Ref: 22A12.

The authors declare no conflicts of interest.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Abstract Image

Abstract Image

Abstract Image

2岁以下鸡蛋过敏儿童早期口服巴氏蛋白免疫治疗
致编辑:在欧洲,出生后2年鸡蛋过敏的总发生率为0.84%(西班牙为0.78%)。很少有关于幼儿口服免疫治疗(OIT)安全性的出版物[2-4]。我们的目的是评估2岁以下对鸡蛋过敏的患者使用巴氏蛋白进行OIT后脱敏的可能性。这是一项前瞻性观察性分析研究,招募了2岁以下对ige介导的鸡蛋过敏的儿童,并接受了含有巴氏消毒液体蛋清的OIT (Huevos guillemaden S.L.)。在西班牙萨拉戈萨Clínico Lozano Blesa医院过敏科就诊的儿童被招募。所有符合纳入标准的患者均被连续纳入。本研究得到了自治区研究伦理委员会Aragón的批准,并获得了父母双方的知情同意。入选标准为:食入鸡蛋后即刻反应史(&lt; 1h);IgE &gt; 0.35 kU/L和/或皮肤点刺试验(SPT)轮≥3mm至至少1个鸡蛋部分(蛋清、蛋黄、卵清蛋白或卵粘液样蛋白);和口服食物挑战(OFC)阳性的煮鸡蛋。除最近3个月内有过敏反应史(根据Sampson标准[5]诊断)或有≥2次即刻反应者外,所有患者均行OFC。分别在T1(基线)、T2(剂量递增期结束)和T3 (T2后6个月)进行SPT和特异性IgE (sIgE)、特异性IgG4 (sIgG4)和sIgE/总IgE比率的测定。在诱导阶段,在医院每周增加巴氏消毒蛋白的剂量(支持信息S1:表S1)。最后的剂量是30毫升蛋清(3300毫克蛋白质,一个中等大小的鸡蛋的蛋清含量)。在增加剂量之间,每天在家中重复临床耐受的剂量,直到下一次就诊。在T2访问期间进行天然生鸡蛋的OFC以验证完全脱敏。维持期持续6个月,包括每隔一天给药总剂量(30ml),持续15天,然后每周至少3次食用1个以不同方式制备的鸡蛋(煮、炒、烤等),包括未煮熟的制剂(蛋黄酱、慕斯等),直到T3随访。通过家长报告来监测依从性。共纳入31例患者,其中女性17例(54.8%),男性14例(45.2%)。首次出现症状的平均年龄为9.6个月(SD 2.48)。OIT开始时的中位年龄为14个月(范围9-26)。中位诊断年龄为11个月(IQR: 3.71)。15例(48.39%)患者有特应性皮炎病史;11例(35.48%)患者既往有喘息症状。有其他食物过敏史11例(35.48%),有变应性疾病家族史15例(53.57%)。SPT轮径、sIgE水平和sIgE/总IgE比值均有统计学意义(p≤0.001)的降低(表1)。T2时sIgG4升高,随后在T3时略有下降(图1),但未观察到显著差异。诱导期出现不良反应24例(77.42%),轻度皮肤反应71例(65.14%);胃肠道作用31例(28.44%);鼻结膜炎7例(6.42%)。大多数事件自行解决或口服抗组胺药。不需要肾上腺素。30例患者T2时OFC为阴性。一名患者的OIT剂量达到22毫升,由于家庭原因停止了研究,6个月时只能耐受含有烤鸡蛋和少量煮鸡蛋的食物。另一名OFC阴性的患者随后拒绝维持摄入,只接受烤鸡蛋和鸡蛋痕迹。6例(19.35%)患者在维持期出现反应:4例皮肤反应,2例胃肠道反应。所有这些反应都很轻微,并没有阻止患者随后继续食用鸡蛋。Giavi[2]报告6个月时OFCs为负的比率为36%。在我们的研究中,在随访期间,93.54%(29/31)的家长报告他们的孩子仍然处于脱敏状态,因此没有进行OFC。实现完全脱敏的比例(对中等大小的鸡蛋,从生鸡蛋到煮熟鸡蛋都没有反应)高于之前的研究(64%-84%)[4,6]。OIT并非没有风险,但我们的不良反应率与已发表的系统评价一致。我们的患者都不需要肾上腺素,然而在一项由Vazquez-Ortiz等人进行的年龄较大的儿童研究中,50名5-18岁的儿童中有26%需要肾上腺素。与我们的研究类似,OIT后的免疫学变化在之前的一些研究中已经被描述过[2-4]。我们研究的一个优势是我们的患者年龄小:最近的花生和牛奶试验表明,早期干预可以改善OIT bbb的结果。 另一种方法是使用巴氏消毒的蛋清,本研究选择它是因为它的稳定性、可重复性、过敏性、易于给药、低成本和微生物安全性。我们的研究受限于相对较短的随访期,没有评估长期耐受性,缺乏随机化,以及由于缺乏对照组而导致统计推断的潜在妥协。也有可能存在选择偏差(例如,家庭在高等教育中心追求OIT的积极性很高)。虽然我们的研究结果似乎表明早期口服免疫治疗对卵子脱敏的发展是有效的,但我们认为需要进一步的对照和随机研究来证实这一说法。Silvia Karina Carrión Sari:资金获取,调查,形式分析,写作-原始草案,可视化,软件,数据策展。路易斯Martínez-Lostao:写作-审查和编辑,监督,调查,项目管理。卡洛斯Colás桑兹:监督,方法论,写作-审查和编辑,概念化,调查。María Teresa Sobrevía Elfau:概念化,方法论,调查,写作-审查和编辑,监督,验证。这项研究由SEAIC(西班牙过敏症和临床免疫学学会)基金会资助,参考文献:22A12。作者声明无利益冲突。支持本研究结果的数据可根据通讯作者的合理要求提供。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical and Translational Allergy
Clinical and Translational Allergy Immunology and Microbiology-Immunology
CiteScore
7.50
自引率
4.50%
发文量
117
审稿时长
12 weeks
期刊介绍: Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书